Generics BRIC (Brazil, Russia, India, China) Industry Guide 2015-2024

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2015-2024

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $101,698.1 million in 2019. Russia was the fastest growing country with a CAGR of 11.8% over the 2015-19 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of $69,811.0 million in 2019. This was followed by India, Russia and Brazil with a value of $16,448.5, $9,127.7, and $6,310.9 million, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of $89,577.3 million in 2024, followed by India, Russia, Brazil with expected values of $23,292.4, $11,252.0 and $8,175.3 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
- Leading company profiles reveal details of key generics market players BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to Buy

- What was the size of the BRIC generics market by value in 2019?
- What will be the size of the BRIC generics market in 2024?
- What factors are affecting the strength of competition in the BRIC generics market?
- How has the market performed over the last five years?
- How large is the BRIC generics market in relation to its regional counterparts?

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 BRIC Generics
2.1. Industry Outlook
3 Generics in Brazil
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Generics in China
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 Generics in India
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Generics in Russia
6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
7 Company Profiles
7.1. Sanofi SA
7.2. EMS SA
7.3. Ache Laboratorios Farmaceuticos SA
7.4. Eurofarma Laboratorios SA
7.5. Teva Pharmaceutical Industries Limited
7.6. Mylan N.V.
7.7. China Grand Pharmaceutical and Healthcare Holdings Limited
7.8. Pfizer Inc.
7.9. Sun Pharmaceutical Industries Ltd
7.10. Lupin Ltd
7.11. Aurobindo Pharma Ltd
7.12. Cipla Limited
7.13. Krka, d. d., Novo mesto
7.14. Abbott Laboratories
8 Appendix
8.1. Methodology
8.2. About MarketLine

List Of Tables

Table 1: BRIC generics industry, revenue($m), 2015-24
Table 2: BRIC generics industry, revenue($m), 2015-19
Table 3: BRIC generics industry, revenue($m), 2019-24
Table 4: Brazil generics market value: $ million, 201519
Table 5: Brazil generics market volume: % of total pharma, 201519
Table 6: Brazil generics market geography segmentation: $ million, 2019
Table 7: Brazil generics market value forecast: $ million, 201924
Table 8: Brazil generics market volume forecast: % of total pharma, 201924
Table 9: Brazil size of population (million), 201519
Table 10: Brazil gdp (constant 2005 prices, $ billion), 201519
Table 11: Brazil gdp (current prices, $ billion), 201519
Table 12: Brazil inflation, 201519
Table 13: Brazil consumer price index (absolute), 201519
Table 14: Brazil exchange rate, 201519
Table 15: China generics market value: $ billion, 201519
Table 16: China generics market volume: % of total pharma, 201519
Table 17: China generics market geography segmentation: $ billion, 2019
Table 18: China generics market value forecast: $ billion, 201924
Table 19: China generics market volume forecast: % of total pharma, 201924
Table 20: China size of population (million), 201519
Table 21: China gdp (constant 2005 prices, $ billion), 201519
Table 22: China gdp (current prices, $ billion), 201519
Table 23: China inflation, 201519
Table 24: China consumer price index (absolute), 201519
Table 25: China exchange rate, 201519
Table 26: India generics market value: $ billion, 201519
Table 27: India generics market volume: % of total pharma, 201519
Table 28: India generics market geography segmentation: $ billion, 2019
Table 29: India generics market value forecast: $ billion, 201924
Table 30: India generics market volume forecast: % of total pharma, 201924
Table 31: India size of population (million), 201519
Table 32: India gdp (constant 2005 prices, $ billion), 201519
Table 33: India gdp (current prices, $ billion), 201519
Table 34: India inflation, 201519
Table 35: India consumer price index (absolute), 201519
Table 36: India exchange rate, 201519
Table 37: Russia generics market value: $ billion, 201519
Table 38: Russia generics market volume: % of total pharma, 201519
Table 39: Russia generics market geography segmentation: $ billion, 2019
Table 40: Russia generics market value forecast: $ billion, 201924
Table 41: Russia generics market volume forecast: % of total pharma, 201924
Table 42: Russia size of population (million), 201519
Table 43: Russia gdp (constant 2005 prices, $ billion), 201519
Table 44: Russia gdp (current prices, $ billion), 201519
Table 45: Russia inflation, 201519
Table 46: Russia consumer price index (absolute), 201519
Table 47: Russia exchange rate, 201519
Table 48: Sanofi SA: key facts
Table 49: Sanofi SA: Annual Financial Ratios
Table 50: Sanofi SA: Key Employees

List Of Figures

Figure 1: BRIC generics industry, revenue($m), 2015-24
Figure 2: BRIC generics industry, revenue($m), 2015-19
Figure 3: BRIC generics industry, revenue($m), 2019-24
Figure 4: Brazil generics market value: $ million, 201519
Figure 5: Brazil generics market volume: % of total pharma, 201519
Figure 6: Brazil generics market geography segmentation: % share, by value, 2019
Figure 7: Brazil generics market value forecast: $ million, 201924
Figure 8: Brazil generics market volume forecast: % of total pharma, 201924
Figure 9: Forces driving competition in the generics market in Brazil, 2019
Figure 10: Drivers of buyer power in the generics market in Brazil, 2019
Figure 11: Drivers of supplier power in the generics market in Brazil, 2019
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2019
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2019
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2019
Figure 15: China generics market value: $ billion, 201519
Figure 16: China generics market volume: % of total pharma, 201519
Figure 17: China generics market geography segmentation: % share, by value, 2019
Figure 18: China generics market value forecast: $ billion, 201924
Figure 19: China generics market volume forecast: % of total pharma, 201924
Figure 20: Forces driving competition in the generics market in China, 2019
Figure 21: Drivers of buyer power in the generics market in China, 2019
Figure 22: Drivers of supplier power in the generics market in China, 2019
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2019
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2019
Figure 25: Drivers of degree of rivalry in the generics market in China, 2019
Figure 26: India generics market value: $ billion, 201519
Figure 27: India generics market volume: % of total pharma, 201519
Figure 28: India generics market geography segmentation: % share, by value, 2019
Figure 29: India generics market value forecast: $ billion, 201924
Figure 30: India generics market volume forecast: % of total pharma, 201924
Figure 31: Forces driving competition in the generics market in India, 2019
Figure 32: Drivers of buyer power in the generics market in India, 2019
Figure 33: Drivers of supplier power in the generics market in India, 2019
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2019
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2019
Figure 36: Drivers of degree of rivalry in the generics market in India, 2019
Figure 37: Russia generics market value: $ billion, 201519
Figure 38: Russia generics market volume: % of total pharma, 201519
Figure 39: Russia generics market geography segmentation: % share, by value, 2019
Figure 40: Russia generics market value forecast: $ billion, 201924
Figure 41: Russia generics market volume forecast: % of total pharma, 201924
Figure 42: Forces driving competition in the generics market in Russia, 2019
Figure 43: Drivers of buyer power in the generics market in Russia, 2019
Figure 44: Drivers of supplier power in the generics market in Russia, 2019
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2019
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2019
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available